Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Roman Vion1, Maxime Fontanilles1, Frédéric Di Fiore1

  • 1Département d'oncologie médicale, centre Henri-Becquerel, 1, rue d'Amiens, 76000 Rouen, France Normandie Univ, UNIROUEN, Inserm U1245, IRON Group, Normandy Centre for Genomic and Personalized Medicine, Université de Rouen.

Bulletin Du Cancer
|December 31, 2021
PubMed
Summary

Liquid biopsy offers a non-invasive approach to analyze breast cancer characteristics. This method shows potential to complement or even replace traditional tumor biopsies for better treatment decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.

EJNMMI research·2026
Same author

Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol.

BMJ open·2026
Same author

Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France).

EClinicalMedicine·2026
Same author

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Cancer chemotherapy and pharmacology·2026
Same author

Peri-Operative Detection of Circulating Tumor DNA Using a Customized NGS Tumor-Informed Assay in Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma.

International journal of cancer·2026

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genetics

Background:

  • Tumor biopsy is critical for breast cancer diagnosis, subtype classification, and identifying targetable molecular alterations like hormone receptors, ERBB2, PIK3CA, and ESR1 mutations.
  • Tumor heterogeneity and plasticity can limit the accuracy of tumor biopsy data, impacting treatment selection.
  • Liquid biopsy, utilizing circulating tumor DNA and cells, provides a non-invasive alternative for cancer detection and characterization.

Purpose of the Study:

  • To evaluate the utility of liquid biopsy in enhancing or replacing data obtained from traditional tumor biopsies for breast cancer management.
  • To assess the role of liquid biopsy in overcoming limitations posed by tumor heterogeneity and plasticity.

Main Methods:

  • This review synthesizes current research on liquid biopsy techniques, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs).
Keywords:
ADN tumoral circulantBiopsie liquideBreast cancerCancer du seinCellule tumoraleCirculating tumor DNACirculating tumor cellLiquid biopsycirculante

Related Experiment Videos

  • The methodology involves analyzing studies that compare liquid biopsy findings with those from conventional tumor biopsies in breast cancer patients.

    • Main Results:

    • Liquid biopsy can detect key molecular alterations, such as hormone receptor status and specific mutations (e.g., PIK3CA, ESR1), non-invasively.
    • Circulating tumor DNA and cells show promise in reflecting tumor characteristics, potentially overcoming issues of spatial and temporal heterogeneity.
    • Studies indicate that liquid biopsy can provide complementary information to tumor biopsies and, in some contexts, may offer a viable alternative.

    Conclusions:

    • Liquid biopsy represents a valuable tool in breast cancer diagnostics, offering a less invasive method to assess tumor molecular profiles.
    • It has the potential to improve treatment decisions by providing real-time, comprehensive data that complements or potentially replaces information from tumor biopsies.
    • Further research is warranted to fully integrate liquid biopsy into routine clinical practice for breast cancer management.